Header Logo

Jie Wu

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
AddressBRC 411 B
975 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA273168     (WU, JIE)Jul 1, 2022 - Jun 30, 2027
    NIH
    Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
    Role: Principal Investigator
    R01CA242845     (WU, JIE)Sep 1, 2020 - May 31, 2025
    NIH
    Blocking tumor progression in therapy-responsive RET aberration-associated cancer
    Role: Principal Investigator
    R01CA178456     (WU, JIE)Jul 8, 2013 - Apr 30, 2019
    NIH
    Roles of PTPN11 in regulating and driving epithelial cancer
    Role: Principal Investigator
    R21CA175603     (WU, JIE)Apr 1, 2013 - Sep 30, 2015
    NIH
    Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo
    Role: Principal Investigator
    R56CA077467     (WU, JIE)Jan 1, 1999 - Jul 31, 2011
    NIH
    Modulation of ErbB Signaling
    Role: Principal Investigator
    R01CA077467     (WU, JIE)Jan 1, 1999 - Apr 30, 2009
    NIH
    Modulation of ErbB Signaling
    Role: Principal Investigator
    R29CA077467     (WU, JIE)Jan 1, 1999 - Dec 31, 2003
    NIH
    SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Khatri U, Dayal N, Owusu KB, Hunjan MK, Pandey S, Harper HA, McMahan C, Elzey BD, Shen T, Hu X, Evans KW, El-Sheikh A, Jo SJ, Holtsberg FW, Aman MJ, Meric-Bernstam F, Woo S, Sintim HO, Wu J. Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy. RSC Med Chem. 2025 Aug 13; 16(8):3541-3550. PMID: 40496186; PMCID: PMC12147034.
      Citations:    
    2. Khatri U, Gouda MA, Pandey S, Chauhan NK, Shen T, Hu X, Li M, Huang S, Subbiah V, Wu J. Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Lett. 2025 Jan 06; 611:217444. PMID: 39778760.
      Citations:    Fields:    
    3. Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024 Mar 04; 8(1):62. PMID: 38438731; PMCID: PMC10912412.
      Citations: 8     
    4. Hu X, Liu X, Khatri U, Wu J. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resist Updat. 2023 May; 68:100958. PMID: 36990046.
      Citations: 6     Fields:    Translation:HumansCells
    5. Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu J. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48. PMID: 34099825.
      Citations: 28     
    6. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819. PMID: 33617938.
      Citations: 27     Fields:    Translation:Humans
    7. Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268. PMID: 33161056.
      Citations: 99     Fields:    Translation:Humans
    8. Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. RET kinase alterations in targeted cancer therapy. Cancer Drug Resist. 2020; 3(3):472-481. PMID: 35582449.
      Citations: 11     
    9. Terzyan SS, Shen T, Liu X, Huang Q, Teng P, Zhou M, Hilberg F, Cai J, Mooers BHM, Wu J. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J Biol Chem. 2019 07 05; 294(27):10428-10437. PMID: 31118272.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    10. Liu X, Shen T, Mooers BHM, Hilberg F, Wu J. Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018 09; 175(17):3504-3515. PMID: 29908090.
      Citations: 51     Fields:    Translation:Humans
    11. Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, Wu J. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia. 2018 05; 32(5):1246-1249. PMID: 29568093.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    12. Cress WD, Yu P, Wu J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. Int J Biochem Cell Biol. 2017 10; 91(Pt B):98-101. PMID: 28504190; PMCID: PMC5641230.
      Citations: 17     Fields:    Translation:HumansCells
    13. Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, Wu J. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther. 2016 10; 15(10):2521-2529. PMID: 27496134.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    Wu's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (60)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (58)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _